Srnalytics is a technology company.
Srnalytics has raised $1.0M across 1 funding round.
Srnalytics has raised $1.0M in total across 1 funding round.
# sRNAlytics: High-Level Overview
sRNAlytics is a biotechnology company that develops small RNA biomarker discovery technology to accelerate drug development and enable precision medicine diagnostics.[1][3] Founded in 2016, the company combines next-generation sequencing and data science to identify disease-associated small RNA biomarkers, addressing a critical bottleneck in pharmaceutical R&D: the 92% failure rate of new drug development.[1] By incorporating biomarker-driven patient selection into clinical trials, sRNAlytics helps increase drug success rates by approximately three times.[1]
The company serves two primary markets: pharmaceutical developers seeking to improve drug discovery and clinical trial outcomes, and physicians and patients requiring better diagnostic tools for disease understanding and stratification.[1] Its flagship offering, sRNA-FIND, is a biomarker discovery service that enables customers to submit samples and receive actionable insights into disease classification and drug response prediction.[1] The platform has demonstrated the ability to classify 31 different types of cancer and stratify patients based on clinical outcome measures.[1]
# Origin Story
sRNAlytics was founded in 2016 by Dr. David W. Salzman, who serves as President and CEO.[1][3] Salzman's motivation emerged from recognizing a fundamental inefficiency in drug development: the lengthy diagnostic timelines and high failure rates in clinical trials, particularly in neurodegenerative diseases where misdiagnosis is endemic.[3] The company's founding vision centered on transforming small RNAs into the next generation of biomarkers—a shift that could fundamentally improve how diseases are understood and treated.[3]
The company gained early validation through IndieBio, a leading early-stage biotech accelerator, which recognized the potential of its platform technology.[3] By the time of its participation in accelerator programs, sRNAlytics had already developed proprietary "Research Use Only" tests demonstrating clinical utility in cancer classification and patient stratification.[1]
# Core Differentiators
# Role in the Broader Tech Landscape
sRNAlytics operates at the intersection of three converging biotech trends: the precision medicine movement, the AI-driven biomarker discovery revolution, and the urgent need to improve pharmaceutical R&D efficiency. The company's timing is particularly relevant given the pharmaceutical industry's mounting pressure to reduce drug development costs and failure rates—a challenge that has only intensified as clinical trial complexity and patient recruitment difficulties have grown.
The company's small RNA focus represents a differentiated approach within the broader biomarker discovery space, which has become increasingly crowded with genomics and proteomics platforms. By identifying molecular pathways through small RNA analysis, sRNAlytics offers a complementary technology that addresses diagnostic challenges where traditional approaches fall short, particularly in neurodegenerative diseases where diagnostic accuracy remains poor.[3]
The company's influence extends to accelerating the adoption of biomarker-driven drug development—a paradigm shift that regulatory agencies increasingly expect and that investors view as de-risking clinical programs.
# Quick Take & Future Outlook
sRNAlytics (now operating as GateHouse Bio following a rebrand)[3][6] is positioned to capitalize on the pharmaceutical industry's structural shift toward precision medicine and biomarker-driven development. The company's $7.9M in funding to date and lean team of 11-50 employees suggest it remains in early growth stages, with significant runway ahead.[3]
The critical question for the company's trajectory is whether its small RNA platform can achieve the "universal disease classifier" status leadership envisions. If successful, sRNAlytics could become a foundational technology layer for drug developers across therapeutic areas—similar to how sequencing platforms became essential infrastructure. Conversely, the company must navigate the challenge of translating research-stage biomarkers into clinically validated, regulatory-approved diagnostics, a path that historically requires substantial capital and time.
The rebranding to GateHouse Bio signals an evolution toward RNA therapeutics development, suggesting the company may be expanding beyond biomarker discovery into therapeutic design—a natural extension that could unlock additional value but also increases execution complexity.
Srnalytics has raised $1.0M in total across 1 funding round.
Srnalytics's investors include Mayfield, SOSV.
Srnalytics has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in November 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2017 | $1.0M Seed | Mayfield, SOSV |